TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells

Cellular Physiology and Biochemistry

Volumn 32, Issue 2, 2013, Pages 253-263

  Jeong, Geun Ok ^a   Shin, Sang Hun ^a   Seo, Eun Jin ^a   Kwon, Yang Woo ^a   Heo, Soon Chul ^a   Kim, Ki Hyung ^a   Yoon, Man Soo ^a   Suh, Dong Soo ^a   Kim, Jae Ho ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Lysophosphatidic acid; Migration; Ovarian cancer; Proliferation; TAZ

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PDZ PROTEIN; PROTEIN; RECEPTOR BLOCKING AGENT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR YAP1; TRANSCRIPTIONAL CO ACTIVATOR WITH PDZ BINDING MOTIF;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; WESTERN BLOTTING; GENE TARGETING; GENETIC TRANSCRIPTION; OVARIAN CANCER CELL LINE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOXAZOLES; LYSOPHOSPHOLIPIDS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NITRILES; OVARIAN NEOPLASMS; PROPIONATES; PROTEIN STABILITY;

EID: 84885573480     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000354434     Document Type: Article

References (32)

1. Aoki J: Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004;15:477-489. (Pubitemid 38953944)
2. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-591. (Pubitemid 37328830)
3. Moolenaar WH: Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem 1995;270:12949-12952.
4. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, Igarashi Y, Tigyi G: Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002;277:21197-21206. (Pubitemid 34952255)
5. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-233.
6. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001;290:302-313. (Pubitemid 32217542)
7. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-723. (Pubitemid 28405297)
8. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y: Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006;66:3006-3014.
9. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, FangX, Mills GB: Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008;100:1630-1642.
10. Blaho VA, Hla T: Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011;111:6299-6320.
11. Contos JJ, Ishii I, Chun J: Lysophosphatidic acid receptors. Mol Pharmacol 2000;58:1188-1196.
12. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH: International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010;62:579-587.
13. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S: Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway. Cancer Res 2004;64:4209-4217. (Pubitemid 38802425)
14. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB: TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005;309:1074-1078. (Pubitemid 41134465)
15. Hong W Guan KL: The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012;23:785-793.
16. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB: TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000;19:6778-6791. (Pubitemid 32011671)
17. Pan D: Hippo signaling in organ size control. Genes Dev 2007;21:886-897. (Pubitemid 46625638)
18. Zeng Q, Hong W: The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008;13:188-192. (Pubitemid 351318373)
19. Wang K, Degerny C, Xu M, Yang XJ: YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 2009;87:77-91.
20. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008;28:2426-2436. (Pubitemid 351429986)
21. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL: TEAD mediates YAP-dependentgene induction and growth control. Genes Dev 2008;22:1962-1971. (Pubitemid 352008643)
22. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W: A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008;68:2592-2598. (Pubitemid 351556257)
23. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, Guan KL: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012;150:780-791.
24. Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GM, Liu J, Peters EC, Wu X: Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol 2012;19:955-962.
25. Mo JS, Yu FX, Gong R, Brown JH, Guan KL: Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 2012;26:2138-2143.
26. Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, Gierschik P, Giehl K: Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK J Cell Sei 2003;116:3835-3846. (Pubitemid 37185312)
27. Du J, SunC, Hu Z, YangY, Zhu Y, Zheng D, Gu L, LuX: Lysophosphatidic acid induces MDA-MB-231 breast cancercells migration through activation of PI3K/PAK1/ERK signaling. PLoS One 2010;5:el5940.
28. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T: Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 2012;490:547-551.
29. ONeill E, Kolch W: Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 2005;4:365-367. (Pubitemid 41359716)
30. Cai H, Xu Y: The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 2013;11:31.
31. Artemenko Y, Batsios P, Borleis J, Gagnon Z, Lee J, Rohlfs M, Sanseau D, Willard SS, Schleicher M, Devreotes PN: Tumor suppressor Hippo/MSTl kinase mediates Chemotaxis by regulating spreading and adhesion. Proc Natl Acad Sei USA 2012;109:13632-13637.
32. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010;70:8517-8525.